Medical Device News Magazine

Forma Medical Launches OptimalHT the World’s First Minimally Invasive Instrumented Hammertoe Arthrodesis Procedure After 50+ Procedures

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Forma Medical, an emerging innovator in medical device technologies, announces today the launch of OptimalHT, the world’s first instrumented Minimally Invasive Surgery (MIS) Hammertoe Arthrodesis procedure, that has treated more than 50 hammertoe deformities. OptimalHT received FDA approval in July and is the company’s inaugural product launch.

“It’s no secret that minimally invasive surgery is the future of Foot and Ankle care,” said Dr. Noman Siddiqui, DPM, LifeBridge Health, Baltimore. “The novel OptimalHT approach for digital correction is ideal for less invasive surgery in the foot to reduce edema, expedite recovery, and achieve the results my patients demand.”

Less invasive than other hammertoe-specific products on the market, OptimalHT is a uniquely instrumented procedure designed to provide repeatable outcomes with minimal incisions. It is also more cost effective and scalable than other attempts at hammertoe-specific products.

“Receiving our first FDA approval and launching the OptimalHT system represents a pivotal moment for Forma Medical,” said James Gault, Vice President of Forma Medical. “With this FDA approval, we now have a platform to launch life-changing systems across multiple anatomies. We are continuing to push the envelope and expand our portfolio to advance patient care.”

According to the US Census Bureau, the country is seeing unprecedented growth in the active aging population. With the number of people experiencing painful hammertoe deformities at an all-time high, and expected to rise, the need to better meet patient expectations is imperative.

“Retrograde k-wire fixation has been an acceptable treatment for decades, yet I’ve recently come to appreciate that some patients are returning to my practice years later with recurrent toe deformities. When I give them the choice, they also seem to be less tolerant of the pins sticking out of the toe and more inclined to pursue a quicker return to standard footwear,” says Jesse Doty, MD, Erlanger Health System, Chattanooga. “With OptimalHT, it’s been seamless for me to incorporate the proven results of a k-wire or to take it a step further with more reliable fixation in a repeatable way that my patients find less inconvenient.”

Forma Medical will debut OptimalHT at the American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting in September. For more information about Forma Medical and to learn about the company’s groundbreaking procedures, please visit www.formamedical.com or www.MIShammertoe.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”